Literature DB >> 3914545

A review of metabolite kinetics.

K S Pang.   

Abstract

The importance of metabolites as active and toxic entities in drug therapy evokes the need for an examination of metabolite kinetics after drug administration. In the present review, emphasis is placed on single-compartmental characteristics for a drug and its primary metabolites under linear kinetic conditions. The determination of the first-order elimination rate constants for drug and metabolite are also detailed. For any ith primary metabolite mi formed solely in liver, kinetic parameters with respect to primary metabolite formation under first-order conditions require a comparison of the areas under the metabolite concentration-time curve after drug and preformed metabolite administrations. These area ratios hold regardless of the number of noneliminating compartments for the drug and metabolite. These parameters include fmi and gmi, the fractions of total body clearance that respectively furnishes mi to the general circulation and forms mi, and hmi, the fraction of hepatic clearance responsible for the formation of mi. Moreover, the fraction of dose dmi converted to form mi is defined with respect to the route of drug administration. The inherent assumption of these estimates, however, requires that the extent of sequential elimination of the generated mi be identical to the extent of metabolism of preformed mi. Discrepancies have been found, and may be attributed mostly to the uneven distribution of drug-metabolizing activities as well as to the presence of diffusional barriers. Other linear systems that involve mi formation from multiple organs are briefly described.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3914545     DOI: 10.1007/bf01058905

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  41 in total

1.  EXCRETION AND THE ACCRUAL OF DRUG METABOLITES.

Authors:  A J CUMMINGS; B K MARTIN
Journal:  Nature       Date:  1963-12-28       Impact factor: 49.962

2.  Pharmacokinetics of isoniazid and some metabolites in man.

Authors:  H G Boxenbaum; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1976-08

3.  Theoretical relationships between area under the curve and route of administration of drugs and their precursors for evaluating sites and pathways of metabolism.

Authors:  K S Pang; J R Gillette
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

4.  A theoretical examination of the effects of gut wall metabolism, hepatic elimination, and enterohepatic recycling on estimates of bioavailability and of hepatic blood flow.

Authors:  K S Pang; J R Gillette
Journal:  J Pharmacokinet Biopharm       Date:  1978-10

5.  Dose- and time-dependent elimination of acetaminophen in rats: pharmacokinetic implications of cosubstrate depletion.

Authors:  R E Galinsky; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1981-10       Impact factor: 4.030

6.  Treatment of data from drug urinary excretion.

Authors:  B K Martin
Journal:  Nature       Date:  1967-04-15       Impact factor: 49.962

7.  Kinetic considerations relating to the accrual and elimination of drug metabolites.

Authors:  A J Cummings; B K Martin; G S Park
Journal:  Br J Pharmacol Chemother       Date:  1967-02

8.  Sequential first-pass elimination of a metabolite derived from a precursor.

Authors:  K S Pang; J R Gillette
Journal:  J Pharmacokinet Biopharm       Date:  1979-06

9.  Metabolism of acetaminophen and phenacetin by isolated rat hepatocytes. A system in which the spatial organization inherent in the liver is disrupted.

Authors:  K S Pang; P Kong; J A Terrell; R E Billings
Journal:  Drug Metab Dispos       Date:  1985 Jan-Feb       Impact factor: 3.922

10.  Pharmacokinetics of benzodiazepines. Short-acting versus long-acting.

Authors:  D D Breimer; R Jochemsen; H H von Albert
Journal:  Arzneimittelforschung       Date:  1980
View more
  15 in total

Review 1.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

2.  Physiological modeling of drug and metabolite: disposition of oxazepam and oxazepam glucuronides in the recirculating perfused mouse liver preparation.

Authors:  M V St-Pierre; D van den Berg; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

3.  An initial slope method for model structure: independent estimation of the elimination rate constant of a metabolite.

Authors:  V K Piotrovskii
Journal:  J Pharmacokinet Biopharm       Date:  1991-06

4.  Metabolite mean transit times in the liver as predicted by various models of hepatic elimination.

Authors:  G D Mellick; Y G Anissimov; A J Bracken; M S Roberts
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

5.  Use of metabolite AUC data in bioavailability studies to discriminate between absorption and first-pass extraction.

Authors:  M Weiss
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

6.  In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3-sulfate and trans-resveratrol-3-glucuronide.

Authors:  Satish Sharan; Otito F Iwuchukwu; Daniel J Canney; Cheryl L Zimmerman; Swati Nagar
Journal:  Drug Metab Dispos       Date:  2012-07-17       Impact factor: 3.922

7.  Metabolite formation pharmacokinetics: rate and extent of metabolite formation determined by deconvolution.

Authors:  M D Karol; S Goodrich
Journal:  Pharm Res       Date:  1988-06       Impact factor: 4.200

8.  An area function method for calculating the apparent elimination rate constant of a metabolite.

Authors:  H Y Cheng; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1989-02

9.  Primary, secondary, and tertiary metabolite kinetics.

Authors:  M V St-Pierre; X Xu; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1988-10

10.  Pharmacokinetics of a nootropic agent, BMY-21502, and its metabolites in beagle dogs.

Authors:  N Srinivas; S Kaul
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.